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Oxidation of low-density lipoprotein (LDL) is thought to contribute to ath-
erosclerosis and cardiovascular disease. Consistent with this idea, the antioxi-
dant drug probucol reduces the risk of restenosis, a form of cardiovascular 
disease, in humans. However, a new study now suggests that the protective 
effect of probucol depends not on its ability to inhibit lipid oxidation, but on 
its ability to induce the stress-induced antiinfl  ammatory enzyme heme oxy-
genase (HO)-1. This might explain why other antioxidants, such as vitamin E, 
fail to prevent cardiovascular disease in humans.
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The LDL oxidation hypothesis
Atherosclerosis, a narrowing of blood 
vessels caused by the deposition of in-
fl  ammatory plaques in the vessel wall, is 
the leading cause of death in industrial-
ized society. One important risk factor 
for atherosclerosis is an elevation in a 
particular type of plasma cholesterol 
called LDL. Oxidation of LDL lipids is 
thought to render the lipoprotein ath-
erogenic, because oxidized LDL is more 
readily taken up by macrophages via 
scavenger receptors (for review see ref-
erences 1, 2). Lipid-laden macrophages 
(known as foam cells) are the major 
component of atherosclerotic lesions. 
Macrophages also secrete myeloperoxi-
dase, an infl  ammatory enzyme that gen-
erates an array of oxidizing intermediates 
(2). Oxidation products characteristic of 
myeloperoxidase have been detected in 
human atherosclerotic lesions, implicat-
ing the enzyme in LDL oxidation in 
vivo (2). Oxidized LDL   attracts mono-
cytes and stimulates the production 
of monocyte chemoattractant protein 
(MCP)-1 and other infl  ammatory cyto-
kines, which might contribute to the 
accumulation of phagocytic cells in ves-
sel walls (Fig. 1). Subsequently, simple 
fatty streaks (the earliest stage of the ath-
erosclerotic lesion), which consist ex-
clusively of macrophage foam cells, are 
converted to more complex lesions 
characterized by the immigration of 
smooth muscle cells from the medial 
layer of the artery wall into the suben-
dothelial space. At this late stage of le-
sion development, oxidized LDL may 
convert smooth muscle cells into foam 
cells and also induce smooth muscle 
cells to synthesize extracellular matrix.
Early in vitro experiments showed 
that all of the major cell types found in 
atherosclerotic lesions (endothelial cells, 
smooth muscle cells, monocytes, and 
macrophages) produce reactive inter-
mediates that oxidize LDL (3–5). Mod-
ifi  cation of LDL in these model systems 
requires redox-active metal ions in 
the medium, generates lipid oxidation 
products, and is inhibited by lipid-solu-
ble antioxidants. These data led to the 
hypothesis that lipid oxidation is essen-
tial for rendering LDL atherogenic (Fig. 
2 A), a proposal supported by biochem-
ical and immunological studies showing 
that oxidized LDL and protein-bound 
adducts of lipid oxidation are found in 
atherosclerotic lesions (6, 7). One of the 
most persuasive arguments supporting 
the oxidation model is the fi  nding that 
antioxidants, such as probucol, N,N′-
diphenyl-phenylenediamine, and bu-
tylated hydroxytoluene, which prevent 
the oxidation of LDL in vitro, inhibit 
atherosclerosis in animal models of hy-
percholesterolemia (8–10).
Probucol lowers LDL in hypercho-
lesterolemic humans, but the drug is no 
longer used clinically because it had neg-
ative side eff  ects, including reductions 
in high density lipoprotein (HDL; the 
“good cholesterol”), which protects 
against atherosclerosis, and potentially 
dangerous changes in heart rhythm. Pro-
bucol dramatically reduces atherosclerosis 
in most hypercholesterolemic animals (1, 
2, 8, 9), and LDL isolated from probucol-
treated animals and humans is markedly 
resistant to oxidation ex vivo (10). LDL 
from humans treated with other lipid-
soluble antioxidants (1, 2) is also resistant 
to oxidation, suggesting that antioxidants 
block LDL oxidation and thus inhibit 
vascular disease. However, a study by 
Wu et al. (11) in this issue (p. 1117) 
suggests that the benefi  cial  eff  ect  of 
probucol is unrelated to its antioxidant 
properties. Instead, the compound ap-
pears to exert a wide variety of potent 
antiinfl  ammatory eff  ects that depend on 
the induction of the stress-induced en-
zyme HO-1, which degrades hemoglo-
bin-derived heme to biliverdin, carbon 
monoxide (CO), and iron. This raises the 
possibility that related compounds that 
lack probucol’s potentially deleterious 
side eff  ects may be useful in the preven-
tion of cardiovascular disease in humans, 
and explains why other antioxidants have 
not been successful in treating atheroscle-
rosis and cardiovascular disease.
Vitamin E therapy does not prevent 
cardiovascular disease in humans
The LDL oxidation hypothesis has at-
tracted skepticism in recent years be-
cause clinical trials have failed to show 
that dietary supplementation with vita-
min E, or other antioxidants, reduces 
the incidence of cardiovascular disease. 
The fi  rst prospective trial to test whether 
antioxidants protect against coronary 
artery disease suggested that the risk of 
nonfatal heart attacks in patients with 
cardiovascular disease was signifi  cantly 
lower in those treated with vitamin E 
(12). However, this was a relatively small 
and short-term trial. Two   subsequent 
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of study subjects that were   followed for 
longer periods of time, found that vita-
min E supplementation had no statisti-
cally signifi  cant eff  ect (13, 14). Another 
clinical trial, which followed  40,000 
apparently healthy women for an aver-
age of 10 years, showed that a high dose 
of natural-source vitamin E taken every 
other day did not reduce the occurrence 
of major cardiovascular events, nor did 
it aff   ect overall mortality (15). Thus, 
randomized clinical trials strongly sug-
gest that the antioxidant vitamin E does 
not   prevent cardiovascular disease, lead-
ing many to question the role of LDL 
oxidation in human atherogenesis.
LDL oxidation debunked?
In this issue, the fi  ndings of Wu et al. 
challenge the role of antioxidants and 
LDL oxidation in cardiovascular disease 
(11). They demonstrate that probucol, 
and certain probucol analogues, retard 
vascular disease in three diff  erent ani-
mal models: apolipoprotein E-defi  cient 
mice (a model of hypercholesterolemia-
induced atherosclerosis), obese Zucker 
rats (a model of type 2 diabetes), and 
rabbits with balloon injury of the ca-
rotid artery (a model of restenosis, a 
thickening of the artery wall caused by 
accumulation of smooth muscle cells in 
the subendothelial space). In all three 
models, the ability of the drug to inhibit 
vascular disease depended on the pres-
ence of a sulfur-containing di-thioether 
bridge in the molecule. The presence of 
the two phenol groups alone, on the 
other hand, was not protective. This 
observation is important because the 
antiatherosclerotic eff  ect of probucol is 
generally attributed to the ability of its 
phenol rings to react with and defuse 
one-electron oxidants such as lipid per-
oxyl radicals (1, 2).
Casting further doubt on the role of 
lipid oxidation in these models, Wu et al. 
found that the degree of lipid oxidation 
in vascular tissue failed to correlate with 
the extent of the lesions. In addition, pro-
bucol dithiobisphenol—a di-thioether 
bridge-containing analogue of probu-
col—protected against atherosclerosis 
but did not reduce plasma   cholesterol 
levels. These observations strongly sug-
gest that the protective eff  ects of pro-
bucol do not involve lipid oxidation or 
cholesterol reduction.
Potential alternative targets of pro-
bucol are two-electron oxidants, which 
react rapidly with di-thioether bridges 
(11). This may be important because 
hypochlorous acid (HOCl), a two-
  electron oxidant generated by myelo-
peroxidase, has been implicated in 
oxidative damage in human atheroscle-
rotic lesions (2). Recent studies indicate 
that HDL isolated from the blood of 
  humans with established cardiovascular 
disease contains elevated levels of chlo-
rinated tyrosine, a characteristic product 
of HOCl produced by myeloperoxidase 
(16, 17). Moreover, in vitro oxidation of 
the HDL-associated protein, apolipo-
protein A-I, impaired the ability of this 
protein to remove cholesterol from cells. 
These observations suggest that protein 
oxidation—rather than lipid oxidation—
might be crucial for atherogenesis.
Probucol targets HO-1
Rather than antioxidant activity, Wu 
et al. trace the antiatherogenic eff  ect 
of probucol and its analogues to the 
  induction of HO-1. CO, a product 
of heme degradation by HO-1, has 
been shown to inhibit endothelial cell 
apoptosis, prevent smooth muscle cell 
  pro  liferation, and inhibit macrophage 
production of infl  ammatory mediators, 
all of which may be important in vascu-
lar protection (18). Another HO-1 by-
product, biliverdin, has also been shown 
to exert antiinfl  ammatory  eff  ects  on 
various cell types. Perhaps because of 
these eff  ects, the induction of HO-1 is 
protective in animal models of infl  am-
matory diseases, such as ischemia-reper-
fusion injury and chronic graft rejection 
(for review see reference 18). HO-1 is 
expressed in aortic tissue after injury 
and was recently shown to help control 
intimal hyperplasia, another form of 
vascular disease (19).
Wu et al. found that levels of HO-1 
increased in the aortas of hypercholes-
terolemic rabbits after balloon injury 
if the animals were treated with probu-
col or an analogue containing the di-
thioether bridge. If the rabbits were 
treated with an analogue containing 
only the phenol groups, on the other 
hand, no HO-1 induction occurred 
(11). The protection against vascular 
disease in this model (based on a reduc-
tion in intimal hyperplasia) also required 
the presence of a di-thioether bridge 
and was independent of the phenol 
groups. The animals that were pro-
tected against disease also had enhanced 
Figure 1.  Initiation and progression of atherosclerotic lesions. LDL enters the subendothelial 
space and is oxidized. Oxidized LDL (OxLDL) promotes monocyte adhesion to injured or infl  amed 
epithelium and migration into the artery wall, where the cells differentiate into macrophages. OxLDL 
also binds to scavenger receptors on macrophages. This binding triggers uptake of OxLDL, converting 
macrophages into lipid-laden foam cells. Subsequently, smooth muscle cells migrate into the subendo-
thelial space, where they accumulate and produce extracellular matrix, two important components 
of more advanced atherosclerotic lesions.COMMENTARY
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aortic reendothelialization, a process re-
quired for the repair of injured vessels.
Inhibition of HO-1 with a synthetic 
inhibitor negated the benefi  cial eff  ects of 
probucol treatment, thus directly linking 
HO-1 induction with the probucol-in-
duced inhibition of vascular injury. Sim-
ilar results were observed in Zucker rats 
and in the carotid arteries of rabbits sub-
jected to balloon injury. Thus, in three 
diff  erent models of vessel injury, treat-
ment with probucol or an analogue con-
taining a di-thioether bridge was strongly 
associated with vascular protection. It is 
also important to note that vitamin E, 
which did not induce HO-1, was not 
protective in these models (11).
Probucol lowers the risk for restenosis 
in humans
Are these observations relevant to the 
prevention of human vascular disease? 
Patients suff  ering from unstable angina 
(chest pain resulting from acute block-
age of coronary arteries) or extensive 
chronic blockage of cardiac arteries are 
often treated with percutaneous angio-
plasty, a procedure in which a balloon 
catheter is inserted into the lumen of 
the occluded artery and expanded to 
disrupt the atherosclerotic plaque, thus 
clearing the arterial blockage. A major 
drawback of this intervention is the 
rapid rethickening (restenosis) of the 
treated vessel, which occurs in approxi-
mately half of subjects who receive no 
additional treatment. In a large clinical 
trial of subjects with coronary artery 
blockage, probucol therapy reduced the 
incidence of restenosis by almost 50% 
(20). In contrast, intervention with an 
antioxidant “cocktail” of vitamin E, 
β-carotene, and vitamin C failed to af-
fect the rate of restenosis. Probucol was 
also protective in another trial, which 
assessed the extent of coronary artery 
restenosis in angioplasty patients using 
intravascular ultrasound (21). In a third 
study, probucol treatment induced the 
regression of carotid atherosclerotic le-
sions in asymptomatic patients with 
high cholesterol, and also reduced the 
incidence of major cardiovascular events 
(22). Thus, probucol, but not vitamin E, 
appears to inhibit restenosis in people 
who have undergone angioplasty.
It is important to point out that the 
underlying mechanisms of atherosclero-
sis and restenosis injury are thought to 
be diff  erent. Thus, the earliest cellular 
event in atherosclerosis is the appear-
ance of macrophage foam cells in the 
artery wall, with the subsequent accu-
mulation of smooth muscle cells in the 
subendothelial space. In contrast, the 
hallmark of restenosis is the selective ap-
pearance of smooth muscle cells in the 
subintimal space with little evidence of 
macrophage foam cells. However, the 
observation that probucol appears to be 
eff  ective in animal models of both types 
of vascular injury suggests that these dis-
eases might have common pathophysi-
ologic mechanisms—perhaps involving 
endothelial injury or smooth muscle cell 
migration and proliferation (Fig. 2 B).
Probucol therapy in humans has 
  potentially deleterious side eff  ects.  It 
markedly reduces levels of HDL, which 
protects arteries from unregulated cho-
lesterol accumulation and atherosclero-
sis. It may also predispose humans to 
dangerous changes in electrical heart 
rhythms. These factors have precluded 
its widespread use in human clinical 
  trials. However, the probucol analogue 
AGI-1067 (which contains the di-thio-
ether bridge) does not cause electrical 
abnormalities and appears to lower 
HDL levels only modestly (23). Like 
probucol, AGI-1067 reduced the ex-
tent of coronary artery restenosis in pa-
tients (21). It also exerts a wide variety 
of antioxidant and anti-infl  ammatory 
eff  ects in vitro, and inhibits atheroscle-
rosis in hypercholesterolemic animals 
(for review see reference 23). A large 
clinical trial is in progress to determine 
whether AGI-1067 prevents cardiovas-
cular events in humans with established 
coronary artery disease. A positive re-
sult would have major implications for 
our understanding of atherogenesis and 
for current approaches to therapy.
Figure 2.  Proposed pathways for the impact of probucol on the pathogenesis of vascular 
disease. (A) LDL in the intima of the artery wall is oxidized with the generation of proatherogenic 
lipid oxidation products (OxLDL). The phenol moiety of probucol blocks this process by acting as a 
scavenger of one-electron oxidants. (B) Vascular injury results in endothelial injury, smooth muscle 
cell (SMC) proliferation, and an infl  ux of infl  ammatory cells and SMCs into the intima. Probucol in-
duces the cellular expression of HO-1, presumably by cells of the artery wall. HO-1 reduces intimal 
hyperplasia and promotes tissue repair by several direct cellular actions. For example, the HO-1 prod-
uct CO has been shown to inhibit endothelial cell (EC) apoptosis, prevent SMC proliferation, and 
inhibit macrophage production of infl  ammatory mediators, all of which may be important in vascu-
lar protection. Probucol may also react with two-electron oxidants that play a role in tissue injury.816  OXIDATION IN CARDIOVASCULAR DISEASE | Heinecke
Future directions
It is noteworthy that the pathways that 
promote oxidative stress in animals and 
humans may diff  er. For example, myelo-
peroxidase promotes oxidative damage 
in the human artery wall (2, 16, 24–26) 
but is undetectable in lesions of mice that 
are prone to atherosclerosis because they 
have high levels of LDL (27). Moreover, 
vitamin E fails to scavenge hypochlorous 
acid, a two-electron oxidant and major 
product of myeloperoxidase that might 
contribute to vessel damage (28). Thus, 
to understand the eff  ects of antioxidants 
on atherosclerosis and vascular injury, it 
will be important to defi  ne the biochem-
ical pathways that promote oxidative re-
actions in the human artery wall and to 
determine whether proposed antioxi-
dants block those reactions. It would be 
of great interest to determine whether 
probucol and AGI-1067 can interrupt 
myeloperoxidase-dependent pathways 
that contribute to oxidative damage of 
proteins in vivo.
The provocative study by Wu et al. 
(11) implicates HO-1 as a molecular tar-
get for probucol in several diff  erent ani-
mal models of vascular injury. In future 
studies, it will be important to explore 
the role of HO-1 in the pathogenesis of 
human vascular disease, to establish how 
probucol induces the expression of the 
enzyme and how HO-1 exerts its anti-
infl  ammatory actions.
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